The FDA approved Anzupgo for the treatment of moderate to severe chronic hand eczema in adults who do not adequately respond ...

The FDA has approved delgocitinib cream as a topical treatment for moderate-to-severe chronic hand eczema (CHE) in adults, ...

The U.S. Food and Drug Administration (FDA) has signed off on the first-ever cream specifically approved for treating chronic ...

The first therapy specifically indicated for chronic hand eczema (CHE) has passed muster at the FDA.

Adult patients with moderate to severe hand eczema with previous treatment failure or in whom topical corticosteroids are ...

LEO Pharma’s Anzupgo (delgocitinib) cream has been approved by the US Food and Drug Administration (FDA) to treat adults with ...

Danish dermatology specialist Leo Pharma has scored an FDA approval that makes its JAK inhibitor cream Anzupgo (del | Despite chronic hand eczema affecting 1 in 10 people worldwide, there was no ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

LEO Pharma Inc. announced today that the Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream for ...

Becoming the first approved treatment for chronic hand eczema in the U.S., Leo Pharma A/S’s Anzupgo (delgocitinib) received ...

Chronic hand eczema is a common dermatological condition that presents itself as hand dermatitis which lasts over 3 months or recurs at least twice a year. 2 Genetic predispositions, ...

BOSTON — Chronic hand eczema can interfere with daily activities and have a significant negative impact on quality of life, according to an abstract presented at the American College of Allergy ...